Logo
x

Search

Subscribe Now

nasal polyps

AstraZeneca and Amgen's Tezepelumab Demonstrates 86% Reduction in Exacerbations in Patients with Asthma and Nasal Polyps

AstraZeneca and Amgen's Tezepelumab Demonstrates 86% Reduction in Exacerbations in Patients with Asthma and Nasal Polyps

  • September 6, 2021
GSK's Nucala (mepolizumab) Receives the US FDA's Approval for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

GSK's Nucala (mepolizumab) Receives the US FDA's Approval for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

  • July 30, 2021
PharmaShots Interview: Genentech's Ted Omachi Shares Insight on the US FDA's Approval of Xolair in Nasal polyps

PharmaShots Interview: Genentech's Ted Omachi Shares Insight on the US FDA's Approval of Xolair in Nasal polyps

  • January 6, 2021
Genentech and Novartis's Xolair (omalizumab) Receives the FDA's Approval for Adults with Nasal Polyps

Genentech and Novartis's Xolair (omalizumab) Receives the FDA's Approval for Adults with Nasal Polyps

  • December 2, 2020
Roche and Novartis Report the US FDA's Acceptance of sBLA for Xolair (omalizumab) to Treat Nasal Polyps

Roche and Novartis Report the US FDA's Acceptance of sBLA for Xolair (omalizumab) to Treat Nasal Polyps

  • December 11, 2019
Novartis Reports Results of Xolair (omalizumab) in Two P-III Studies for Chronic Rhinosinusitis with Nasal Polyps in Adults

Novartis Reports Results of Xolair (omalizumab) in Two P-III Studies for Chronic Rhinosinusitis with Nasal Polyps in Adults

  • June 3, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.